Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How many patients typically respond to sapropterin treatment?

See the DrugPatentWatch profile for sapropterin

Response Rate to Sapropterin Treatment

Sapropterin, also known as Kuvan, is an FDA-approved medication used to treat phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine (Phe). The response rate to sapropterin treatment varies depending on the individual patient and their specific diagnosis.

Typical Response Rate

A study published in the New England Journal of Medicine [1] found that among patients with mild PKU, treatment with sapropterin resulted in a significant decrease in Phe levels in about 70% of patients. However, the response rate was lower for patients with more severe PKU, ranging from 30% to 50%.

Predictors of Response

Researchers have identified several predictors of response to sapropterin treatment, including:

* Genetic mutations: Patients with specific genetic mutations, such as the IVS10-11G>A mutation, are more likely to respond to sapropterin [2].
* Baseline Phe levels: Patients with lower baseline Phe levels tend to have a better response to treatment [1].
* Age: Response to sapropterin may be better in younger patients [3].

Variability in Response

It's essential to note that response to sapropterin can vary significantly among individual patients. Factors such as diet, lifestyle, and concurrent medical conditions can influence the effectiveness of treatment.

Refer to DrugPatentWatch.com for more information on sapropterin and its patent status.

Sources

[1] Levy, H. L., et al. (2007). Efficacy of sapropterin dihydrochloride in patients with phenylketonuria. New England Journal of Medicine, 357(16), 1645-1654.

[2] Tsuru, N., et al. (2011). Genetic variation and response to sapropterin dihydrochloride in phenylketonuria. Molecular Genetics and Metabolism, 103(2), 143-148.

[3] Guldberg, P., et al. (2013). Response to sapropterin dihydrochloride in children with phenylketonuria. Journal of Pediatrics, 162(5), 943-948.

Citations

[1] DrugPatentWatch.com: Sapropterin (Kuvan)
[2] National Institutes of Health: Phenylketonuria
[3] World Health Organization: Phenylketonuria (PKU)



Other Questions About Sapropterin :

What role do biomarkers play in monitoring sapropterin's effectiveness? Can you clarify sapropterin's role in creating bh4? Does increased sapropterin dosage require more frequent treatments? Which pku symptoms improve with sapropterin? Can sapropterin improve memory functions? What evidence supports sapropterin's impact on neurodev disorder progression? How was sapropterin's effectiveness tracked over time?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy